Karaca, F.Keskin, S.Mentes, S.Okten, A., ICavus, G.Arslan, A.Koksal, F.2025-05-102025-05-1020221119-307710.4103/njcp.njcp_1408_212-s2.0-85130862514https://doi.org/10.4103/njcp.njcp_1408_21https://hdl.handle.net/20.500.14720/14069Aim: In this study, we aimed to investigate the interleukin-17A (IL-17A) levels in patients with high-grade glial tumors before receiving radiotherapy, immediately after radiotherapy, and 3 months after radiotherapy. Patients and Methods: A total of 33 patients who applied to Adana City Training and Research Hospital, Department of Radiation Oncology between December 2016 and May 2018 was included in this study. A total of three blood samples was taken from each patient to assess IL-17A levels before and after radiotherapy and 3 months after the completion of radiotherapy. Results: The differences in IL-17A levels between genders were not statistically significant. IL-17A levels progressively decreased after the radiotherapy and 3 months after the radiotherapy as compared to the levels before radiotherapy. However, this was not statistically significant. IL-17A levels in the non-surviving patients were high before and after radiotherapy as compared to the surviving ones, but this was also not statistically significant. Conclusion: As compared to the period before radiotherapy, IL-17A levels tend to decrease in the period of acute and chronic phases of radiotherapy in all patient groups.eninfo:eu-repo/semantics/closedAccessElisaIl-17AMalignant GliomaRadiotherapyArticle255Q4Q258258835593599WOS:000805362600005